Rituximab shows second-line promise in autoimmune limbic encephalitis

Rituximab is an effective and well-tolerated second-line treatment for patients with autoimmune limbic encephalitis, suggests research.
Source: MedWire News - Category: Consumer Health News Tags: Neurology Source Type: news